BioSig Technologies collaborates with Reified Labs

BioSig Technologies announced that it entered a collaboration with Reified Labs to advance its R&D efforts.

The collaboration with Reified Labs, a technical advisory partner, advances the R&D of an AI-based medical device platform. BioSig plans to base the foundational machine learning model for the device on integrated healthcare datasets. That starts with ECG and IECG data acquired by BioSig’s Pure EP platform.

Electrophysiology-focused technological solutions developed under the collaborations may integrate into Pure EP for potential commercial applciation.

Pure EP system combines hardware and software to enable the real-time acquisition of raw signal data. The technology achieves this absent of unnecessary noise or interference.

According to BioSig, Pure EP allows physicians to make informed clinical decisions based on clear and precise data. Pure EP heightens visualization of active signals to facilitate personalized patient care.

“The cutting-edge work this collaboration started in early 2019 to lay a foundation in AI was ahead of the curve, and our initial findings may have several potentially valuable clinical applications worthy of further exploration,” said Kenneth Londoner, chair and CEO of BioSig Technologies, Inc.

Cambridge, Massachusetts-based Reified Labs provides AI-focused technical advisory services to the life sciences industry. Award-winning computer scientist, physicist, entrepreneur, and author Dr. Alexander Wissner-Gross leads the firm.

“The application of AGI and digital signal processing to analyzing signals from the so-called human ‘electrome’ – the set of all electrical and ionic currents in the human body – continues to present a promising opportunity for realizing key medical advances relating to disorders of the peripheral nervous system,” said Dr Wissner-Gross. “We look forward to our forthcoming collaboration with BioSig.” MassDevice